Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Sep;32(9):E40-4.
doi: 10.1002/clc.20475.

Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes

Zhenxian Yan  1 , Yujie Zhou, Yingxin Zhao, Yueping Li, Xiaomin Nie, Zhiming Zhou, Dean Jia
Affiliations
Randomized Controlled Trial

Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes

Zhenxian Yan et al. Clin Cardiol. 2009 Sep.

Abstract

Objective: To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI).

Methods: A total of 240 patients were randomized to either a tirofiban group or a control group.

Results: Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK-MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events (MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1).

Conclusions: The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective.

PubMed Disclaimer

References

    1. Hartman GD. Tirofiban hydrochloride: platelet antiaggregatory GP IIb/IIIa receptor antagonist. Drugs Future 1995; 20: 897–901.
    1. Madan M, Berkawitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation 1998; 98: 2629–2635. - PubMed
    1. Lynch JJ, Cook JJ, Sitko GR, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. Antithrombotic effects of MK‐0383. J Pharmacol Exp Ther 1995; 272: 20–32. - PubMed
    1. The PRISM Study Investigators . A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–1505. - PubMed
    1. PRISM‐PLUS Study Investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non‐Q‐wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497. - PubMed

Publication types

MeSH terms